Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could breathing hydrogen protect the aging brain?

NCT ID NCT07757542

Symptom relief Sponsor: University of Ostrava Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study tests whether inhaling a low concentration of hydrogen gas each day is safe and might help people with mild cognitive impairment. Participants, aged 50 to 80, will breathe in 4% hydrogen for one hour daily over 12 weeks, followed by 12 weeks without it. Researchers will monitor for side effects and use memory and naming tests to see if cognitive function changes. The goal is to gather initial safety data and see if this approach warrants larger studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Molecular hydrogen gas administered by inhalation
What this could lead to
If safe and effective, daily hydrogen inhalation could offer a simple, non-drug way to help preserve memory and thinking in people with mild cognitive impairment.
What could go wrong
This is a small pilot study, not designed to prove effectiveness. It focuses on safety and feasibility, and results may not generalize. The therapy's benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients diagnosed with mild cognitive impairment (MCI) with an overall good health condition * generally good health, with the ability to perform daily activities independently (modified Rankin score 0-2, Barthel index minimum 70 points) * age between 50 and 80 years, ensuring inclusion of individuals within the typical risk range for cognitive decline * a reliable study partner or caregiver who can provide accurate information about the participant's cognitive and functional abilities throughout the study * stable medical condition, without major fluctuations in health status that could interfere with cognitive assessments * signed informed consent, ensuring that participants understand the study protocol and potential risks Exclusion Criteria: * pregnancy or lactation, as the safety of hydrogen inhalation therapy in these populations has not been established * use of medications or investigational treatments that could significantly affect cognitive function or interfere with study outcomes * history of severe psychiatric disorders such as major depression, bipolar disorder, or schizophrenia, which may independently influence cognitive performance * history of cerebrovascular events, including recent stroke or transient ischemic attack, which may confound cognitive outcomes * severe cardiovascular diseases, including uncontrolled hypertension, recent myocardial infarction, or heart failure, that could pose additional risks during the study * chronic kidney disease (stage 3 or higher), as impaired renal function may alter systemic metabolism and affect the study's findings * significant respiratory disorders, such as severe chronic obstructive pulmonary disease (COPD) or restrictive lung diseases, that could impact the safety of hydrogen inhalation * known hypersensitivity or allergic reactions to materials used in the hydrogen delivery system, such as nasal cannulas or facial masks * recent participation in another clinical trial within the past 90 days, to prevent potential interactions and ensure unbiased study results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment (MCI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Respiratory Aspiration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment (MCI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cerebrovaskularni poradna s.r.o.

    RECRUITING

    Ostrava, Moravian-Silesian Region, 70200, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.